Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a
promising treatment option for patients with HCC.
In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a
metastatic mechanism encourages exploring adjuvant/neoadjuvant strategies targeting tumor
growth and metastatic escape in the context of percutaneous thermal ablation for small HCC.
Local ablation of HCC is therefore an "ideal" setting for testing atezolizumab + bevacizumab
in combination with ablation, with the aim of reducing the risk of recurrence.